Crohn's Disease and Diverticulitis. Difficult Differential Diagnosis and Differential Therapy in Case of Coincidence: In a 50-year-old patient both Crohn's disease localized in the sigma and diverticulosis had been diagnosed previously. Because of differential therapeutic consequences and for prognostic considerations the coincidence of these diseases requires accurate endoscopic, histologic and radiologic evaluation during exacerbations with acute symptoms in order to differentiate between active Crohn's disease and diverticulitis.
Efficacy of Gemfibrozil in Patients with Hyperlipoproteinemia (HLP) Type II a, II b and IV - Results of a Long-term Trial: Study objective: Influence of Gemfibrozil in a daily dose of 900 mg on atherogenic and antiatherogenic lipids in patients with HLP type II a, II b and IV. Design: Open unicenter trial over 72 weeks. Patients: 121 out-patients with HLP type II a (n = 27), II b (n = 53) and IV (n = 41). Interventions: 900 mg Gemfibrozil daily in the evening. End points: Reduction of atherogenic and increase of antiatherogenic lipids. Main results: In HLP type II a Gemfibrozil lowered total cholesterol, LDL-cholesterol and triglycerides by 11, 12 and 27%, respectively, whereas HDL-cholesterol increased by 7% (all changes significant). In HLP-type II b total cholesterol (- 13%), triglycerides (- 36%) and HDL-cholesterol (+ 11%) were changed significantly. In HLP-type IV triglycerides decreased by 35%, whereas LDL-cholesterol and HDL-cholesterol increased by 19% and 18%, respectively (all changes significant). Gemfibrozil had no influence on liver and kidney function, whereas thrombocytes increased. Subjective side effects, mostly gastro-intestinal symptoms, occurred in 13% of patients. Conclusion: Gemfibrozil in a daily dose of 900 mg, given in the evening, can be recommended for long-term therapy of HLP-types II a, II b and IV.
